Showing results (11-20 of 101) with videos related to

Sort By:
Pageof 11
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 10, 2009
Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histologyRafael Molina, Josep M Augé, Xavier Bosch, et al.
Genes, Chromosomes & Cancer|January 21, 2004
Intronic deletion affecting a negative regulatory region of TP73 is related to breast and colorectal carcinomasCristina Peña, Jose M Garcia, Gemma Dominguez, et al.
Future Oncology (London, England)|February 13, 2015
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trialFilippo de Marinis, Alain Vergnenegre, Antonio Passaro, et al.
Annals of Surgical Oncology|October 7, 2003
Intratumoral heterogeneity in microsatellite alterations in BRCA1 and PTEN regions in sporadic colorectal cancerJose M Garcia, Rufo Rodriguez, Javier Silva, et al.
The Journal of Pathology|January 27, 2004
Altered expression of the ZBRK1 gene in human breast carcinomasVanesa Garcia, Gemma Domínguez, José M García, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2016
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLCAlain Vergnenegre, Bartomeu Massuti, Filippo de Marinis, et al.
BMC Pulmonary Medicine|March 1, 2017
Transbronchial and transesophageal fine-needle aspiration using a single ultrasound bronchoscope in the diagnosis of locoregional recurrence of surgically-treated lung cancerJosé Sanz-Santos, Pere Serra, Felipe Andreo, et al.
Endocrine-Related Cancer|December 26, 2008
Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancerRosa Gallego, Jordi Codony-Servat, Xabier García-Albéniz, et al.
Oncotarget|March 4, 2021
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approachEnric Carcereny, Alonso Fernández-Nistal, Araceli López, et al.
The Journal of Surgical Research|February 18, 2011
Single nucleotide polymorphisms in tobacco metabolism and DNA repair genes and prognosis in resected non-small-cell lung cancerMarc Campayo, Nuria Viñolas, Alfons Navarro, et al.
Pageof 11